ArticleNPJ science of food2026
Rice bran protein peptide PVLWGVPKG alleviate gastric mucosal damage induced by Helicobacter pylori infection.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The aim of this study was to investigate the effect of PVLWGVPKG (PV9) on gastric mucosa cell damage induced by Helicobacter pylori infection. PV9 intervention could significantly reduce the number of Helicobacter pylori adhering to GES-1 cells (p <0.05). Molecular docking showed that PV9 and its degraded fragments could bind to Helicobacter pylori adhesins, and hydrogen bonds might be the main driving force. Dot blot assays confirmed the binding between PV9 and adhesins SabA and BabA in vitro. The protective mechanism of PV9 against Helicobacter pylori infection-induced GES-1 damage cells was analyzed. It was found that PV9 could accelerate the clearance of reactive oxygen species, reduce mitochondrial membrane potential, improve cell cycle arrest, and prevent apoptosis. In addition, PV9 can also significantly improve the antioxidant capacity of cells (SOD, GSH-Px, and CAT), reducing the content of pro-inflammatory factors (IL-1β, IL-6, IL-8, IL-18, and TNF-α) and increasing the content of anti-inflammatory factors (IL-10). The results of qRT-PCR showed that PV9 could protect GES-1 cells by regulating the expression of apoptotic factors. Moreover, the TLR4/MyD88/NF-κB signaling pathways may play a significant role in this process. This study provides a new idea for antagonizing Helicobacter pylori infection with active peptide components.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.